Community Acquired Pneumonia Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 70 pages | ID: C04A454799ACEN
VPAResearch

Abstracts

Community Acquired Pneumonia Drug pipeline report- 2020 is an annual R&D review of Community Acquired Pneumonia pipeline candidates. The report presents the current status of all major Community Acquired Pneumonia therapeutic compounds. Detailed insights into Community Acquired Pneumonia pipeline development, current status, companies, drug profiles and Community Acquired Pneumonia preclinical and clinical trials are included.

2020 Community Acquired Pneumonia Pipeline Market Insights
Community Acquired Pneumonia disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Community Acquired Pneumonia therapies, pipeline by phase and others are included.

Community Acquired Pneumonia pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Community Acquired Pneumonia Therapeutic Drug candidates
Both active and inactive Community Acquired Pneumonia pipeline drug candidates are included in the report

Community Acquired Pneumonia Clinical Trials and preclinical Studies
Community Acquired Pneumonia In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Community Acquired Pneumonia pipeline market developments
Community Acquired Pneumonia Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Community Acquired Pneumonia pipeline companies in active development
The report analyzes Community Acquired Pneumonia pipeline of the below companies-

Basilea Pharmaceutica Ltd , BioAegis Therapeutics, Inc., Biotest AG , Combioxin SA, Fogangren Bio-Pharma Ltd, InflaRx NV, ioGenetics, LLC, Iterum Therapeutics Plc , KYORIN Pharmaceutical Co.,Ltd, Meiji Seika Pharma Co Ltd, Melinta Therapeutics, Inc., Merck & Co Inc, Paratek Pharmaceuticals, Inc., ProThera Biologics LLC, TaiGen Biotechnology Co., Ltd., Takeda Pharmaceutical Co Ltd, Tetraphase Pharmaceuticals Inc., TiGenix NV, Wockhardt Ltd

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
19 Companies investing in Community Acquired Pneumonia pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Community Acquired Pneumonia pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. COMMUNITY ACQUIRED PNEUMONIA PIPELINE MARKET INSIGHTS, 2020

1.1 Community Acquired Pneumonia Disease Overview
1.2 Community Acquired Pneumonia Drug Pipeline Snapshot, 2020
  1.2.1 Community Acquired Pneumonia Pipeline Drugs by Phase
  1.2.2 Community Acquired Pneumonia Pipeline Drugs by Company
  1.2.3 Community Acquired Pneumonia Pipeline Drugs by Mechanism of Action
  1.2.4 Community Acquired Pneumonia Pipeline Drugs by Route of Administration

2. COMMUNITY ACQUIRED PNEUMONIA COMPANY WISE PIPELINE DETAILS

Basilea Pharmaceutica Ltd Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
BioAegis Therapeutics, Inc. Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Biotest AG Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Combioxin SA Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Fogangren Bio-Pharma Ltd Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
InflaRx NV Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
ioGenetics, LLC Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Iterum Therapeutics Plc Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
KYORIN Pharmaceutical Co.,Ltd Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Meiji Seika Pharma Co Ltd Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Melinta Therapeutics, Inc. Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Merck & Co Inc Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Paratek Pharmaceuticals, Inc. Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
ProThera Biologics LLC Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
TaiGen Biotechnology Co., Ltd. Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Takeda Pharmaceutical Co Ltd Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tetraphase Pharmaceuticals Inc. Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
TiGenix NV Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details
Wockhardt Ltd Community Acquired Pneumonia Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. COMMUNITY ACQUIRED PNEUMONIA DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. COMMUNITY ACQUIRED PNEUMONIA PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts